Open access
Aug 2026
Anti-4CB1: A Novel Selective HVEM-Blocking Antibody Enhancing T-Cell and Macrophage Immunity Against Solid Tumors.
Immune checkpoint inhibitors (ICIs) have improved cancer outcomes; however, many patients fail to respond, highlighting the need for novel targets. HVEM (Herpes Virus Entry Mediator) is an immune regulator with both inhibitory and stimulatory functions, making it a promising therapeutic candidate. We have developed Ant...
Gilli Galore-Haskel, Efrat Merhavi-Shoham, M. Shapiro et al.
· Molecular Cancer Therapeutic... · 0 citations